Gilead Sciences (B): Implementing the Gilead Access Program for HIV Drugs Case Solution And Analysis, HBR Case Study Solution & Analysis of Harvard Case Studies

Describes Gilead Sciences' first experience of the program access for the delivery of its antiviral drugs Viread to developing countries in Africa. In April 2003, Gilead announced a program Gilead Access, to make the company's new drug Viread available, at no profit to Gilead, in developing countries. Viread is a significant advance in the treatment of antiretroviral drugs for HIV / AIDS, once a day, the dosage, effectiveness and a significant improvement in the side effect profile. Gilead executives expected Access Program, to have a direct positive impact on the treatment of HIV / AIDS in the world's poorest countries. One year after implementation, however, Access Program has not led to widespread use of Viread in Africa. Having learned from earlier mistakes, Gilead had to make significant changes to improve the program. She also wanted to expand the program to access a wider access to treatment of middle-income regions. "Hide
by David P. Baron, Keith Krehbiel, Brian Tayan Source: Stanford Graduate School of Business 11 pages. Publication Date: March 21, 2007. Prod. #: P53B-PDF-ENG